OptiNose (NASDAQ:OPTN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of OptiNose (NASDAQ:OPTN) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

OptiNose Trading Down 15.5 %

Shares of OPTN opened at $0.51 on Wednesday. The firm has a market cap of $76.47 million, a PE ratio of -1.81 and a beta of -0.07. The firm has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.96. OptiNose has a 1-year low of $0.50 and a 1-year high of $2.10.

Institutional Investors Weigh In On OptiNose

Several hedge funds and other institutional investors have recently modified their holdings of OPTN. Vanguard Group Inc. increased its stake in shares of OptiNose by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock worth $6,194,000 after purchasing an additional 62,906 shares in the last quarter. Oracle Investment Management Inc. bought a new position in OptiNose in the 1st quarter worth $474,000. Rosalind Advisors Inc. boosted its holdings in OptiNose by 66.2% in the 2nd quarter. Rosalind Advisors Inc. now owns 7,547,148 shares of the company’s stock worth $7,849,000 after buying an additional 3,005,659 shares during the period. Easterly Investment Partners LLC boosted its holdings in OptiNose by 10.2% in the 2nd quarter. Easterly Investment Partners LLC now owns 2,246,224 shares of the company’s stock worth $2,336,000 after buying an additional 208,185 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock worth $3,037,000 after buying an additional 81,233 shares during the period. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.